November 30, 2017 – Scenic appoints Alexandra Glucksmann as member of its Board of Directors
Scenic Biotech BV, a pioneer in the discovery of genetic modifiers to enable the development of disease modifying therapeutics for rare genetic disorders and other devastating illnesses, today announced that it has appointed Alexandra Glucksmann to its Board of Directors
Alexandra holds a Ph.D. with honors from the University of Chicago and was a post-doctoral fellow at the M.I.T.. She spent 13 years at Millennium Pharmaceuticals, ultimately serving as Vice President. She was Senior VP at Cerulean Pharma. Most recently, Alexandra served as founding chief operating officer of Editas Medicine Inc.. Alexandra is currently President and CEO at Cedilla Therapeutics and serves on the board of Women in the Enterprise of Science and Technology (WEST).